Document:

EX-10.11

 Exhibit 10.11 

EMPLOYMENT AGREEMENT 

This Employment Agreement (“Agreement”) is made among Cano Health, LLC (the “Company”), JAWS Acquisition Corp., a Cayman
Islands exempted company (the “Parent”) and Dr. Richard Aguilar (the “Executive”). Effective upon the consummation of the transactions contemplated by that certain Business Combination Agreement, dated as of the date hereof,
by and between the Parent, and Primary Care (ITC) Holdings, LLC, a Delaware limited liability company and indirect owner of all outstanding membership interests of the Company (the “Business Combination Agreement”), this Agreement
supersedes in all respects all prior agreements between the Executive and the Company or any of its subsidiaries regarding the subject matter herein, including, without limitation, the Employment Agreement between the Executive and the Company,
dated as of December 23, 2016 (the “Prior Agreement”). 
 WHEREAS, effective upon the consummation of the transactions
contemplated by the Business Combination Agreement (the “Effective Date”), the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the new terms and conditions
contained herein. 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: 
 1. Employment.

 (a) Term. Unless the Executive’s employment terminates sooner in accordance with the provisions of Section 4, the Company
shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement commencing as of the Effective Date and continuing until the third (3rd) anniversary of the
Effective Date (the “Initial Term”); provided that the employment period (the “Term”) shall be renewed automatically for successive periods of one (1) year (each a “Renewal Term”) unless the Company delivers to the
Executive, or the Executive delivers to the Company, written notice of the Company’s or the Executive’s, as applicable, election not to renew the Term for the following Renewal Term (a
“Non-Renewal Notice”), within ninety (90) days prior to the expiration of the Initial Term or the then current Renewal Term, as applicable. 

(b) Position and Duties. The Executive shall serve as the Chief Clinical Officer of the Company and shall have such powers and duties
that are customary for a Chief Clinical Officer and such other additional duties as may from time to time be prescribed by the Chief Executive Officer (the “CEO”) or the board of directors of the Company. At the Executive’s election,
the Executive may also provide professional medical services to patients of the Company which shall include, but not be limited to, consultations, examinations, call coverage, treatments and reports (the “Medical Services”). For the
avoidance of doubt, the Medical Services shall not include any services the Executive provides in connection with the Clinical Business (as defined below). The Executive shall devote the Executive’s full working time and efforts to the business
and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board of Directors of the Parent (the “Board”), continue the Executive’s existing clinical
business in Los Angeles, California (the “Clinical Business”) or engage in religious, charitable or other community activities, as long as such services and activities do not interfere with the Executive’s performance of the
Executive’s duties to the Company. 

  
 1 

 (c) Medical Judgment. With respect to the Executive’s provision of Medical
Services (if any) only, neither the Company nor the Parent shall (i) inhibit the freedom necessary for the Executive to practice medicine in a manner which assures that the interests of the Company’s patients are given primary
consideration; (ii) exercise any control or discretion over the means, manner or method by which the Executive provides professional services hereunder that would be detrimental to any patient; or (iii) make any treatment decisions for any
patient receiving medical care by the Executive, except to the extent required by applicable state or federal law. The Executive, in his sole discretion, shall accept patients, provided that the Executive shall not discriminate against anyone on the
basis of sex, race, national origin, color, religion, disability, handicap, age, sexual orientation, ability to pay or insurance carrier/payer. Any referrals made by the Executive shall be based upon the medical judgment of the Executive while
acting in the best interest of patients. 
 2. Additional Duties in Connection with Medical Services (if Any). 

In the event that the Executive provides Medical Services pursuant to Section 1(b), the parties agree to the additional provisions set
forth on Exhibit A of this Agreement. 
 3. Compensation and Related Matters. 

(a) Base Salary. The Executive’s initial base salary shall be paid at the rate of $300,000 per year. Thereafter, the
Executive’s base salary shall be subject to periodic review by the Compensation Committee of the Board (the “Compensation Committee”) or the Board, provided that the Executive’s base salary may be increased but not
decreased. The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for executive officers. 

(b) Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the
Compensation Committee from time to time (“Incentive Compensation”). The Executive’s target annual Incentive Compensation shall not be less than 40 percent of the Executive’s Base Salary (referred to herein as “Target
Bonus”), subject to increase as determined by the Board or the Compensation Committee. The actual amount of the Executive’s annual Incentive Compensation, if any, shall be determined in the sole discretion of the Board or the Compensation
Committee, subject to the terms of any applicable Incentive Compensation plan that may be in effect from time to time, which terms shall generally be no less favorable in the aggregate to the terms of any Incentive Compensation plan applicable to
other executive officers of the Company. Except as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in the applicable Incentive Compensation plan or this Agreement, the Executive must be employed by the
Company on the date such Incentive Compensation is paid in order to earn or receive any annual Incentive Compensation. 

  
 2 

 (c) Expenses. The Executive shall be entitled to receive prompt reimbursement for all
reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers. 

(d) Other Benefits. The Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit
plans in effect from time to time, subject to the terms of such plans. 
 (e) Paid Time Off. The Executive shall be entitled to take
paid time off in accordance with the Company’s applicable paid time off policy for executives, as may be in effect from time to time. 

(f) Parent Equity. The Parent will grant Executive the following equity awards (the “Equity Awards”): 

(i) Initial Grant of Stock Options: On the Closing Date, Parent shall grant a stock option to purchase 600,700 shares of class A common
stock of Parent (“Parent Stock”), which shall be subject to the terms and conditions of the Cano Health, Inc. 2021 Stock Option and Incentive Plan (the “2021 Plan”) and an equity award agreement substantially in the form of the Non-Qualified Stock Option Agreement attached hereto as Exhibit C. 
 (ii) Initial Grant of
Restricted Stock Units: Immediately subsequent to the filing of a Form S-8 by Parent, which filing shall be made by Parent as soon as reasonable possible after the Closing Date, Parent shall grant an award
of restricted stock units in respect of 200,000 shares of Parent Stock, which shall be subject to the terms and conditions of the Cano Health, Inc. 2021 Plan and an equity award agreement substantially in the form of the Restricted Stock Unit Award
Agreement attached hereto as Exhibit D. 
 (iii) Annual Equity Award: Subject to approval by the Board or Compensation
Committee, the Executive shall also be eligible to receive an annual equity award with a target value of $646,000 (the “Target Annual Equity Award Value”) at substantially the same time as annual equity awards are granted to other
executive officers of the Company, which shall be subject to the terms and conditions of the 2021 Plan and shall be comprised of a stock option to purchase Parent Stock subject to a form of award agreement substantially in the form of Non-Qualified Stock Option Agreement attached hereto as Exhibit E and/or restricted stock units in respect of Parent Stock subject to an award agreement substantially in the form of Restricted Stock Unit
Award Agreement attached hereto as Exhibit F (with such adjustments thereto as reasonably determined by the Board in its sole discretion, provided that with respect to the first annual equity award following the Effective Date, any such
adjustments to the aggregate value, nature of award and performance hurdles shall be immaterial), as allocated among options and RSUs, as determined by the Board or Compensation Committee. 

4. Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement under the following
circumstances: 
 (a) Death. The Executive’s employment hereunder shall terminate upon death. 

  
 3 

 (b) Disability. The Company may terminate the Executive’s employment if the
Executive is disabled and unable to perform or expected to be unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180
days (which need not be consecutive) in any twelve (12) month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing
position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or
the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The
Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue
shall be binding on the Executive. Nothing in this Section 4(b) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601
et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq. 
 (c) Termination by the Company for
Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean any of the following: 

(i) expulsion, suspension, material restriction or loss of license that materially restricts the Executive’s ability to perform duties
customary for a Chief Clinical Officer by any professional medical or governmental licensing organization (including, if applicable, any applicable state medical licensing board); provided, however, that this Agreement shall not terminate pursuant
to this subsection: (a) prior to the termination of the time permitted by law for the Executive to take a timely appeal of such action or (b) if a timely appeal is taken, while such appeal is pending but in no event more than ninety
(90) days following the taking of such appeal; provided, however, that from the time of such action until the expiration of the time periods in clauses (a) and (b), the Company shall place the Executive on an unpaid leave of absence,
during which time the Company shall have no obligation to pay any compensation to the Executive but the Company will, at the Executive’s election, continue the Executive’s benefits during such leave if the Executive pays or reimburses the
Company for the cost of such benefits; 
 (ii) conduct by the Executive constituting a material act of misconduct solely in connection with
the performance of the Executive’s duties as Chief Clinical Officer, including (A) a willful failure or refusal to perform material responsibilities that have been requested by the CEO, or (B) misappropriation of funds or property of
the Company or Parent or any of their subsidiaries or affiliates other than the occasional, customary and de minimis use of Company or Parent property for personal purposes; 

(iii) Executive’s conviction of or plea of guilty or nolo contendere to (A) any felony or (B) a misdemeanor involving
moral turpitude, deceit, dishonesty or fraud; 

  
 4 

 (iv) a material breach by the Executive of any of the Continuing Obligations (defined
below) or any of the other provisions contained in Section 9 of this Agreement; 
 (v) a material violation by the Executive of any of
the Company’s written employment policies regarding discrimination and harassment; or 
 (vi) the Executive’s failure to
materially cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Board to cooperate, or the willful destruction or failure to preserve documents or other
materials known to be relevant to such investigation (after the Executive receives notices to preserve such documents or other materials) or the willful inducement of others to fail to cooperate or to produce documents or other materials with such
investigation. 
 Provided, however, that the Executive will be provided written notice of any alleged action or inaction giving rise to
“Cause” under clauses (iii), (v) or (vi) describing with reasonable particularity the basis for such “Cause” and will be provided thirty (30) days from the date of such notice to cure such alleged action or inaction. If
timely cured to the Company’s reasonable satisfaction, such occurrence will not constitute “Cause.” 
 (d) Termination by
the Company without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any termination by the Company of the Executive’s employment under this Agreement (other than (x) a termination
for Cause under Section 4(c) or (y) a termination resulting from the death or disability of the Executive under Section 4(a) or (b)), including any such termination resulting from the Company’s election not to renew the Term for
a Renewal Term under Section 4(f), shall be deemed a termination without Cause. 
 (e) Termination by the Executive. The
Executive may terminate employment hereunder at any time for any reason, including but not limited to, Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has completed all steps of the Good
Reason Process (hereinafter defined) following the occurrence of any of the following events without the Executive’s consent (each, a “Good Reason Condition”): 

(i) a diminution in the Executive’s responsibilities, authority or duties; 

(ii) a material diminution in the Executive’s Base Salary, Executive’s Target Bonus, and/or Target Annual Equity Award Value
(collectively, the “Total Target Compensation”), except for across-the-board salary reductions based on the Company’s financial performance similarly
affecting all or substantially all senior management employees of the Company; 
 (iii) a material change in the geographic location at
which the Executive provides services to the Company, such that there is an increase of at least thirty (30) miles of driving distance to such location from the Executive’s principal residence as of such change (provided that the
requirement that the Executive provide services at the location of the current headquarters of the Company shall not trigger “Good Reason”); or 

  
 5 

 (iv) a material breach of this Agreement by the Company. The “Good Reason
Process” consists of the following steps: 
 (v) the Executive reasonably determines in good faith that a Good Reason Condition has
occurred; 
 (vi) the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 75 days of the
first occurrence of such condition; 
 (vii) the Executive cooperates in good faith with the Company’s efforts, for a period of not
less than 30 days following such notice (the “Cure Period”), to remedy the Good Reason Condition; 
 (viii) notwithstanding
such efforts, the Good Reason Condition continues to exist at the end of the Cure Period; and 
 (ix) the Executive terminates employment
within 120 days after the end of the Cure Period. 
 If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not
to have occurred. 
 (f) Termination by Notice of Non-Renewal. Each of the Executive and the
Company may terminate the Executive’s employment by delivering a Non-Renewal Notice within 90 days prior to the expiration of the Initial Term or the then current Renewal Term, as applicable. 

5. Matters related to Termination. 

(a) Notice of Termination. Except for termination as specified in Section 4(a), any termination of the Executive’s employment
by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate
the specific termination provision in this Agreement relied upon. 
 (b) Date of Termination. “Date of Termination” shall
mean: (i) if the Executive’s employment is terminated by death, the date of death; (ii) if the Executive’s employment is terminated on account of disability under Section 4(b) or by the Company for Cause under
Section 4(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company without Cause under Section 4(d), the date on which a Notice of Termination is given or the date
otherwise specified by the Company in the Notice of Termination; (iv) if the Executive’s employment is terminated by the Executive under Section 4(e) other than for Good Reason, 30 days after the date on which a Notice of

  
 6 

 
Termination is given; (v) if the Executive’s employment is terminated by the Executive under Section 4(e) for Good Reason, the date on which a Notice of Termination is given after
the end of the Cure Period; and (vi) if the Executive’s employment is terminated on account of either party providing a Notice of Non-Renewal, the last day of the Initial Term or current Renewal Term
(as applicable). Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company or Notice of Non-Renewal, the Company may unilaterally accelerate the Date of
Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. 
 (c) Accrued
Obligations. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to the Executive’s authorized representative or estate) (i) any Base Salary
earned through the Date of Termination and, if applicable, any accrued but unused vacation through the Date of Termination; (ii) unpaid expense reimbursements (subject to, and in accordance with, Section 3(c) of this Agreement); and
(iii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans
(collectively, the “Accrued Obligations”). 
 (d) Resignation of All Other Positions. To the extent applicable, the
Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive’s employment for any
reason. The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations. 

6. Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason. If the Executive’s
employment is terminated by the Company without Cause as provided in Section 4(d) (including the Company’s delivery of a Non-Renewal Notice as provided in Section 4(f)), or the Executive
terminates employment for Good Reason as provided in Section 4(e), then, in addition to the Accrued Obligations, and subject to the Executive delivering an executed “Separation Agreement and Release of Claims” in the form
attached as Exhibit G (the “Separation Agreement”) and the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement): 

(a) Severance Payments Outside a Change in Control Period. If the date of the Notice of Termination provided under Section 5 is not
within twelve (12) months following a Sale Event (as defined in the 2021 Plan) (a “Change in Control Period”), the Company shall pay the Executive an amount equal to (i) twelve (12) months of the Executive’s Base
Salary (ignoring any reduction that constitutes Good Reason); (ii) any earned but unpaid Incentive Compensation with respect to the completed year prior to the year of the Date of Termination; and (iii) a pro rata portion of the
Executive’s Target Bonus for the year in which the Executive’s employment is terminated (ignoring any reduction that constitutes Good Reason). 

  
 7 

 (b) Severance Payments During a Change in Control Period. If the date of the Notice
of Termination provided under Section 5 is during a Change in Control Period (even if the Date of Termination does not occur during a Change in Control Period), the Company shall pay the Executive an amount in cash equal to (i) 2 times the sum
of (x) the Executive’s Base Salary (ignoring any reduction that constitutes Good Reason) and (y) the average annual Incentive Compensation paid to the Executive in each of the two completed years prior to the year of the
Executive’s Date of Termination (provided that, if Incentive Compensation has not been paid to the Executive for each of the prior two years, such amount shall be the Executive’s Target Bonus for the current year) (ignoring any reduction
that constitutes Good Reason); (ii) a pro rata portion of the Executive’s Target Bonus for the year in which the Executive’s employment is terminated (ignoring any reduction that constitutes Good Reason); (iii) any earned but unpaid
Incentive Compensation with respect to the completed year prior to the year of the Date of Termination; and (iv) full acceleration of vesting of all outstanding equity awards granted by the Parent, including the Equity Awards (with any
performance-based vesting criteria deemed satisfied based on actual performance measured in the Company’s reasonable discretion as of such termination). 

(c) subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper
election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the
monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the twelve (12) month anniversary of the Date of
Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s health continuation rights under COBRA;
provided, however, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716
of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to
tax-related deductions and withholdings and paid on the Company’s regular payroll dates. 
 The amounts payable
under Section 6, to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided,
however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as “non-qualified
deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), shall begin to be paid in the second calendar year by the last day of such
60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of
Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). 

  
 8 

 7. Additional Limitation. 

(a) Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by
the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code, and the
applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the
Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a
higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse
chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A of the
Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing
Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any
amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c). 

(b) For purposes of this Section 7(b), the “After Tax Amount” means the amount of the Aggregate Payments less all federal,
state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal
income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in
each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. 

(c) The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 7(b)(i) shall be made by an
independent (not otherwise employed by the Company), nationally recognized accounting firm selected and paid for by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the
Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the
Executive. 
 8. Section 409A. 

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the
meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive
becomes entitled to under this Agreement or otherwise on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to
Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall 

  
 9 

 
not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from service, or (B) the Executive’s death. If any such
delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. 

(b) All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be
provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of
the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to
reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 

(c) To the extent that any payment or benefit described in this Agreement constitutes
“non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such
payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in
Treasury Regulation Section 1.409A-1(h). 
 (d) The parties intend that this Agreement will be
administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments
hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The
parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and
benefits provided hereunder without additional cost to either party. 
 (e) The Company makes no representation or warranty and shall have no
liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

 9. Continuing Obligations. For purposes of this Agreement, the obligations in this Section 9 shall collectively be referred to
as the “Continuing Obligations.” 

  
 10 

 (a) Non-Competition. The Executive agrees
that during the Term and for two (2) years following the Executive’s termination of employment for any reason (the “Restricted Period”), the Executive shall not, directly or indirectly, own, manage, operate, join, control or
participate in the ownership, management, operation or control of, or be an officer or an employee of any business or organization that provides, directly or indirectly (including as a provider or as a management services organization), in a primary
care clinic setting (which includes without limitation the practice of primary care medicine in a multidisciplinary clinic) professional medical services, diagnostic, therapeutic and ancillary services, nursing and other clinical services,
outpatient healthcare services, pharmacy services or any other services incident to the operation of an internal medicine practice in a primary care clinic setting (each, a “Restricted Business”). The foregoing restriction shall apply
anywhere in the areas where the Company, its subsidiaries, or any subsidiaries of Parent conduct or have conducted a Restricted Business (or have expended material resources or time to plan the conduct of a Restricted Business, which plans remain
active and have not been abandoned) during the Term, including, but not limited to, the United States (including Puerto Rico) (the “Restricted Territory”). Notwithstanding the foregoing, the Parties agree that this Section 9(a) shall
not restrict the Executive from operating the Clinical Business or from owning up to 3% of any class of securities of any person engaged in a Restricted Business if such securities are listed on any national or regional securities exchange or have
been registered under Section 12(g) of the Securities Exchange Act of 1934, as amended, as long as such securities are held solely as a passive investment and not with a view to influencing, controlling or directing the affairs of such person.

 (b) Non-Solicitation. The Executive agrees that, during the Restricted Period, the
Executive will not, directly or indirectly, for himself or on behalf of or in conjunction with any other person, (i) solicit, induce, attempt to solicit or induce, or hire or attempt to hire any person that is, or was within twelve
(12) months prior to the Executive’s termination date, an employee of the Company; provided, however, this Section 9(b) shall not be breached by a solicitation to the general public or through general advertising, or
(ii) solicit, advise or encourage any person, firm, government agency or corporation (a “Customer”), including without limitation any potential customer of the Company that to the Executive’s knowledge was engaged in discussion
with the Company during the Executive’s employment to do business with the Company (or with whom the Executive actively worked during employment), to withdraw, curtail or cancel its business (or potential business) with the Company. 

(c) Non-Disparagement. During the Term and thereafter, the Executive agrees that he will not, at
any time, make, directly or indirectly, any oral or written statements that are disparaging of the Company, its business, its products or services, or any of its present or former officers, directors, members, stockholders, managers or employees.
During the Term and thereafter, the Company agrees that it will not, at any time, make directly or indirectly, any oral or written statements that are disparaging to the Executive. The Executive understands that the Company’s obligations under
this Section 9(c) extend only to the Company’s and Parent’s current executive officers and members of the Board and the Company’s Board of Directors and only for so long as each officer or member is an employee or director of the
Company, or the Parent, as applicable. 
 (d) Third-Party Agreements and Rights. The Executive hereby confirms that the Executive is
not bound by the terms of any agreement with respect to the Clinical Business which restricts in any way the Executive’s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive’s engagement in
any business. The 

  
 11 

 
Executive represents to the Company that the Executive’s execution of this Agreement, the Executive’s employment with the Company and the performance of the Executive’s proposed
duties for the Company will not violate any obligations the Executive may have with respect to the Clinical Business. In the Executive’s work for the Company, the Executive will not disclose or make use of any information in violation of any
agreements with respect to or rights of the Clinical Business, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or
obtained from the Clinical Business. 
 (e) Litigation and Regulatory Cooperation. During and after the Executive’s employment,
the Executive shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences
that transpired while the Executive was employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information. The Executive’s
full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the
Company at mutually convenient times. During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as
any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 9(e). 

(f) Relief. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any
breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, the Executive agrees that if the Executive breaches, or proposes to breach, any portion
of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the
Company. 
 (g) Reasonable Limitation and Severability. The parties agree that the above restrictions on competition are
(i) appropriate and reasonable given the Executive’s role with and knowledge of the Company and Parent, and are necessary to protect the interests of the Company and Parent and (ii) completely severable and independent agreements
supported by good and valuable consideration and, as such, shall survive the termination of this Agreement for any reason whatsoever. The Executive acknowledges that the Executive has carefully considered the terms of this Agreement, including the
restrictive covenants set forth in this Section 9, and acknowledges that if this Agreement is enforced according to its terms, the Executive will be able to earn a reasonable living in commercial activities unrelated to the business of the
Company in locations satisfactory to the Executive. The Executive also acknowledges that the restrictive covenants set forth in this Section 9 are a vital part of and are intrinsic to the ongoing operations of the Company, in light of the
nature of the business of the Company and the unique position, skills and knowledge of the Executive with the Company. The parties further agree that 

  
 12 

 
any invalidity or unenforceability of any one or more of such restrictions on competition shall not render invalid or unenforceable any remaining restrictions on competition. Additionally, should
a court of competent jurisdiction determine that the scope of any provision of this Section 9 is too broad to be enforced as written, the parties hereby authorize the court to reform the provision to such narrower scope as it determines to be
reasonable and enforceable and the parties intend that the affected provision be enforced as so amended. The Executive acknowledges and agrees that to the extent the Executive has breached or is in breach of any of the covenants set forth in
Sections 9(a) or (b), the Restricted Period shall be extended by an amount of time equal to the duration of such breach. 
 10. Stock
Ownership Guidelines. For the avoidance of doubt, any applicable stock ownership guidelines and/or policy of the Company shall not apply to the Executive following the Executive’s termination of employment for any reason. 

11. Proprietary Information and Inventions Agreement. As a condition of the Executive’s continued employment with the Company, the
Executive will sign the Proprietary Information and Inventions Agreement (the “PIIA”), attached hereto as Exhibit B. . Nothing in or about this Agreement (including the PIIA), however, prohibits the Executive
from: (a) filing and, as provided for under Section 21F of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), maintaining the confidentiality of a claim with the Securities and Exchange Commission (the
“SEC”), (b) providing any information about this Agreement to the SEC, or providing the SEC with information that would otherwise violate any section of this Agreement, to the extent permitted by Section 21F of the Exchange Act,
(c) cooperating, participating or assisting in an SEC investigation or proceeding without notifying the Company or (d) receiving a monetary award as set forth in Section 21F of the Exchange Act. 

12. Arbitration of Disputes. 

(a) Arbitration Generally. Any controversy or claim arising out of or relating to this Agreement or the breach thereof or otherwise
arising out of the Executive’s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination or retaliation, whether based on race, religion, national origin, sex, gender, age,
disability, sexual orientation, or any other protected class under applicable law) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement,
under the auspices of JAMS in Miami, Florida in accordance with the JAMS Employment Arbitration Rules, including, but not limited to, the rules and procedures applicable to the selection of arbitrators. The Executive understands that the Executive
may only bring such claims in the Executive’s individual capacity, and not as a plaintiff or class member in any purported class proceeding or any purported representative proceeding.The Executive further understands that, by signing this
Agreement, the Company and the Executive are giving up any right they may have to a jury trial on all claims they may have against each other. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction
thereof. This Section 12 shall be specifically enforceable. Notwithstanding the foregoing, this Section 12 shall not preclude either party from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a
preliminary injunction in circumstances in which such relief is appropriate, including without limitation relief sought in connection with the Continuing Obligations; provided that any other relief shall be pursued through an arbitration proceeding
pursuant to this Section 12. 

  
 13 

 (b) Arbitration Fees and Costs. Each party shall pay its own costs and
attorneys’ fees, if any, in connection with any arbitration. If, however, any party prevails on a statutory or contractual claim that affords the prevailing party attorneys’ fees (including pursuant to this Agreement), the arbitrator may
award attorneys’ fees to the prevailing party to the extent permitted by law. 
 13. Consent to Jurisdiction. To the extent that
any court action is permitted consistent with or to enforce Section 12 of this Agreement, the parties hereby consent to the jurisdiction of the state and federal courts of the State of Florida. Accordingly, with respect to any
such court action, the Executive (a) submits to the exclusive personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise)
with respect to personal jurisdiction or service of process. 
 14. Waiver of Jury Trial. Each of the Executive and the Company
irrevocably and unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE’S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE
COMPANY, INCLUDING WITHOUT LIMITATION THE EXECUTIVE’S OR THE COMPANY’S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT. 

15. Integration. This Agreement, the PIIA, and any other plans or programs referenced herein constitute the entire agreement between the
parties with respect to the subject matter hereof and supersede all prior agreements between the parties concerning such subject matter. 

16. Withholding; Tax Effect. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other
amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or
benefits or for any deduction or withholding from any payment or benefit. 
 17. Successors and Assigns. None of the Executive, the
Company or the Parent may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company or Parent may assign its rights and
obligations under this Agreement (including the Continuing Obligations) without the Executive’s consent to any affiliate or to any person or entity with whom the Company or Parent shall hereafter effect a reorganization or consolidation, into
which the Company or Parent merges or to whom it transfers all or substantially all of its properties or assets; provided further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in
connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section 6 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit

  
 14 

 
of and be binding upon the Executive, the Company and the Parent, and each of the Executive’s, the Company’s and the Parent’s respective successors, executors, administrators,
heirs and permitted assigns. In the event of the Executive’s death after the Executive’s termination of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall
continue such payments to the Executive’s beneficiary designated in writing to the Company prior to the Executive’s death (or to the Executive’s estate, if the Executive fails to make such designation). 

18. Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any
section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to
which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law. 

19. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the
Executive’s employment to the extent necessary to effectuate the terms contained herein. 
 20. Waiver. No waiver of any
provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement,
shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. 
 21.
Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or
certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company or the Parent, at their respective main offices, attention of the
Board. 
 22. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly
authorized representative of the Company and the Parent. 
 23. Effect on Other Plans and Agreements. An election by the Executive to
resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company’s benefit plans, programs or policies.
Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company’s or the Parent’s benefit plans, programs or policies except as otherwise provided in Section 9 hereof, and except that the Executive
shall have no rights to any severance benefits under any Company or Parent severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company or Parent providing for payments or benefits under
such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. 

  
 15 

 24. Governing Law. This is a Florida contract and shall be construed under and be
governed in all respects by the laws of the State of Florida, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law
as it would be interpreted and applied by the United States Court of Appeals for the Eleventh Circuit. 
 25. Counterparts. This
Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. 

IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date. 

 

			
	JAWS Acquisition Corp.
		
	By:	 	
                 

	Its:	 	              

	
	Cano Health, LLC
		
	By:	 	
                     
    

	Its:	 	              

	
	Dr. Richard Aguilar
	
	  

  
 16 

 Exhibit A 

Additional Duties in Connection with Medical Services (if Any) 

In the event the Executive elects to provide the Medical Services pursuant to Section 1(b) of this Agreement, the Executive agrees to the following,
solely to the extent applicable to the provision of Medical Services in the Practicing States (as defined below). 
 (a) Payor Arrangements.

 (i) The Executive shall become and remain, while providing the Medical Services, a participating physician in Medicare, Medicaid and any
other payor arrangements and any prepaid or managed care health care programs as are designated by the Company in the Practicing States for all Medical Services rendered by the Executive to patients who are covered under such programs. 

(ii) The Executive hereby consents to the Company’s release of information regarding the Executive as requested by third party payers
under managed care agreements entered into by the Company, which information must be provided pursuant to the terms and conditions of such managed care agreements. 

(iii) From time to time, the Company may enter into managed care or network agreements with third party payors, employers, or governmental
entities that, among other things, may require the Company and/or the Executive to engage in utilization review or peer review activities. The Executive will fully cooperate in such activities and will comply with any and all reasonable requirements
of any managed care or network agreement to which the Company becomes a party. If required by any managed care entity or network, the Executive will execute the agreement individually, notwithstanding that all fees generated by such agreement will
belong to the Company. 
 (b) Patients and Records of the Company. Without superseding any patient’s right to choose a provider
of health or medical services, the Executive acknowledges that all patients for whom the Medical Services are provided by the Executive shall be patients of the Company and not of the Executive. While providing the Medical Services, the Executive
shall, whenever possible, refer patients to the Company and its affiliates and use the Company and its affiliates when a referral is called for, and the Executive shall not induce, solicit, or encourage any patient who has received or is receiving
health or medical services from the Company or its affiliates to seek such services from another provider/supplier; provided, however, that such requirements shall be waived when: (a) the patient expresses a different choice; (b) the
patient’s insurer determines the provider/supplier; or (c) the referral is not in the best medical interest of the patient in the Executive’s judgment. All medical, patient, business, financial, or other records, papers, and documents
generated by the Executive, the Company, or employees or agents of the Company shall belong to the Company, and the Executive shall have no right to keep or retain such records, papers, or documents after this Agreement is terminated; provided,
however, that upon the request of the Executive after termination, the Company shall provide the Executive with copies of the patient records of patients treated by the Executive at the patient’s request or for such reasonable purposes as
defending against professional liability claims. 

  
 17 

 (c) Additional Duties. The Executive’s duties with respect to the Medical
Services shall also include the following: 
 (i) Complying with and abiding by any policies, procedures, rules, regulations, guidelines and
requirements of the Company, as may be amended, promulgated or eliminated by the Company in its discretion from time to time. 
 (ii)
Complying with any provision of state or federal law, and any regulation thereunder, now in effect or later adopted relating to the Medical Services to be provided under this Agreement and that are applicable to the Executive. The Executive also
agrees to be bound by, and to follow, the provisions of the Company’s privacy policies and practices, as well as other state and federal privacy laws. 

(iii) Preparing and maintaining, or causing to be prepared and maintained, necessary or appropriate reports, claims, correspondence and records
as may be required by state and/or federal law or regulations and/or by Medicare and Medicaid intermediaries and carriers relating to the Medical Services rendered by the Executive under this Agreement. The Executive agrees that the Executive’s
maintenance and retention of all records and reports will be such that the Company can comply with requests and requirements, as may be amended from time-to-time, of
third party payers and other regulatory authorities including, but not limited to, Medicare, Blue Cross, the Comptroller General of the United States and the Department of Health and Human Services. The Executive’s responsibilities with respect
to this subsection, other than the obligation to maintain applicable reports, claims, correspondence and records, will survive termination of the Executive’s employment. All such reports, claims, correspondence and records belong to the Company
and shall be maintained and retained on the Company’s premises 
 (d) Representations, Warranties, and Covenants. During the
provision of the Medical Services, 
 (i) The Executive will maintain a valid and unrestricted license to practice medicine in the states in
which the Executive is licensed to practice medicine as of the Effective Date (such state(s), the “Practicing Sate(s)”) and is registered with such state agencies as may be required to carry out the duties hereunder and to practice as a
physician in the field of medicine in such state(s). 
 (ii) The Executive has not been disciplined by any professional or peer review
organization, governmental or medical staff for any action or omission based on quality of care. 
 (iii) The Executive has and will maintain
a valid and unrestricted license or registration to prescribe drugs, medications, pharmaceuticals or controlled substances as required by the Practicing States. 

  
 18 

 (iv) The Executive is not currently subject to any type of criminal or civil sanction, fine,
civil money penalty, debarment, or threatened with, any investigation, censure, probation, suspension, or other adverse action with respect to the Executive’s medical license in any Practicing State or with respect to the Executive’s
medical staff privileges at any hospital, nursing home or other medical institution; that the Executive is not excluded from participation and is not otherwise ineligible to participate in a “Federal health care program” as defined in 42
U.S.C. § 1320a-7b(f) or in any other state or federal government payment program, including Medicare, Medicaid and TRICARE; and that the Executive, to his knowledge, is not currently under investigation
with respect to his participation in such federal or state health care programs. 
 (v) With the exception of this Agreement, neither the
Executive nor any immediate family member (as defined by 42 C.F.R. § 411.1 et seq. (the “Federal Stark Regulations”)) of the Executive, has any direct or indirect financial relationship (whether an ownership or investment interest, or
a compensation arrangement, all as defined by the Federal Stark Regulations) with any entity (as defined by the Federal Stark Regulations) that provides for the furnishing of designated health services (as defined by the Federal Stark Regulations).
The Executive shall notify the Company immediately, in writing, of any plans for such a financial relationship to be created, or in the case of immediate family members, as soon as the Executive has knowledge of the existence of or plan to create
such a financial relationship. 

  
 19 

 Exhibit B 

PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT 

The following confirms and memorializes an agreement that Cano Health, LLC, a Florida limited liability company (“Company”),
and I (Dr. Richard Aguilar) have had since the commencement of my employment (which term, for purposes of this agreement, shall be deemed to include any relationship of service to Company that I may have had prior to actually becoming an
employee) with Company in any capacity and that is and has been a material part of the consideration for my employment by Company: 
 1. I
have not entered into, and I agree I will not enter into, any agreement either written or oral in conflict with this Agreement or my employment with Company. I will not violate any agreement with or rights of any third party or, except as expressly
authorized by Company in writing hereafter, use or disclose my own or any third party’s confidential information or intellectual property when acting within the scope of my employment or otherwise on behalf of Company. Further, I have not
retained anything containing any confidential information of a prior employer or other third party, whether or not created by me. 
 2.
Company shall own, and I hereby assign to Company, all right, title and interest (including patent rights, copyrights, trade secret rights, mask work rights, sui generis database rights and all other intellectual property rights of any
sort throughout the world) relating to any and all inventions (whether or not patentable), works of authorship, mask works, designs, know-how, ideas and information
(collectively, “Inventions”) made or conceived or reduced to practice, in whole or in part, by me during the term of my employment with Company (collectively, “Company Inventions”), and I will promptly
disclose all Company Inventions to Company. The term “Company Inventions” will not include any Invention for which no equipment, supplies, facilities or trade secret information of the Company was used and which was developed entirely on
my own time, unless (a) the Invention relates (i) to the business of the Company, or (ii) to the Company’s actual or demonstrably anticipated research or development, or (b) the invention results from any work performed by
me for the Company. Without disclosing any third party confidential information, I will also disclose anything I believe is excluded by the foregoing so that Company can make an independent assessment. I shall further assist Company, at
Company’s expense, to further evidence, record and perfect the foregoing assignment and to perfect, obtain, maintain, enforce, and defend any rights specified to be so owned or assigned. I hereby irrevocably designate and appoint Company as my
agent and attorney-in-fact, coupled with an interest and with full power of substitution, to act for and in my behalf to execute and file any document and to do all
other lawfully permitted acts to further the purposes of the foregoing with the same legal force and effect as if executed by me. If I wish to clarify that something created by me prior to my employment that relates to Company’s actual or
proposed business is not within the scope of the foregoing assignment, I have listed it on Appendix A in a manner that does not violate any third party rights or disclose any confidential information. Without limiting Section 1 or
Company’s other rights and remedies, if, when acting within the scope of my employment or otherwise on behalf of Company, I use or (except pursuant to this Section 2) disclose my own or any third party’s confidential information or
intellectual property (or if any Company Invention cannot be fully made, used, reproduced, distributed and otherwise exploited without using or violating the foregoing), Company will have, and I hereby grant Company a perpetual, irrevocable,
worldwide royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such confidential information and intellectual property rights. 

  
 20 

 3. To the extent allowed by law, paragraph 2 includes all rights of paternity, integrity,
disclosure and withdrawal and any other rights that may be known as or referred to as “moral rights,” “artist’s rights,” “droit moral,” or the like (collectively “Moral Rights”). To the extent I
retain any such Moral Rights under applicable law, I hereby ratify and consent to any action that may be taken with respect to such Moral Rights by or authorized by Company and agree not to assert any Moral Rights with respect thereto. I will
confirm any such ratifications, consents and agreements from time to time as requested by Company. 
 4. I agree that all Company Inventions
and all other business, technical and financial information (including, without limitation, the identity of and information relating to customers or employees) I develop, learn or obtain during the term of my employment that relate to Company or the
business or demonstrably anticipated business of Company or that are received by or for Company in confidence, constitute “Proprietary Information.” I will hold in confidence and not disclose or, except within the scope of my employment,
use any Proprietary Information. However, I shall not be obligated under this paragraph with respect to information I can document is or becomes readily publicly available without restriction through no fault of mine. Upon termination of my
employment, I will promptly return to Company all items containing or embodying Proprietary Information (including all copies), except that I may keep my personal copies of (i) my compensation records, (ii) materials distributed to
shareholders generally and (iii) this Agreement. I also recognize and agree that I have no expectation of privacy with respect to Company’s telecommunications, networking or information processing systems (including, without limitation,
stored computer files, email messages and voice messages) and that my activity and any files or messages on or using any of those systems may be monitored at any time without notice. 

5. I agree that during the term of my employment with Company (whether or not during business hours), I will not engage in any activity that is
in any way competitive with the business of Company, and I will not assist any other person or organization in competing or in preparing to compete with any business or demonstrably anticipated business of Company. 

6. I agree that this Agreement is not an employment contract for any particular term and that I have the right to resign and Company has the
right to terminate my employment at will, at any time, for any or no reason, with or without cause. In addition, this Agreement does not purport to set forth all of the terms and conditions of my employment, and, as an employee of Company, I have
obligations to Company which are not set forth in this Agreement. However, the terms of this Agreement govern over any inconsistent terms and can only be changed by a subsequent written agreement signed by the Chief Executive Officer of Company.

 7. I agree that my obligations under paragraphs 2, 3, and 4 of this Agreement shall continue in effect after termination of my employment,
regardless of the reason or reasons for termination, and whether such termination is voluntary or involuntary on my part, and that Company is entitled to communicate my obligations under this Agreement to any future employer or potential employer of
mine. My obligations under paragraphs 2, 3 and 4 also shall be binding upon my heirs, executors, assigns, and administrators and shall inure to the benefit of Company, its subsidiaries, successors and assigns. 

  
 21 

 8. Any dispute in the meaning, effect or validity of this Agreement shall be resolved in
accordance with the laws of the State of Florida, without regard to the conflict of law provisions thereof. I further agree that if one or more provisions of this Agreement are held to be illegal or unenforceable under applicable law, such illegal
or unenforceable portion(s) shall be limited or excluded from this Agreement to the minimum extent required so that this Agreement shall otherwise remain in full force and effect and enforceable in accordance with its terms. This Agreement is fully
assignable and transferable by Company, but any purported assignment or transfer by me is void. I also understand that any breach of this Agreement will cause irreparable harm to Company for which damages would not be an adequate remedy, and,
therefore, Company will be entitled to injunctive relief with respect thereto in addition to any other remedies and without any requirement to post bond. 

9. Pursuant to the federal Defend Trade Secrets Act of 2016, I acknowledge receipt of the following notice: “An individual shall not be
held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or
investigating a suspected violation of law. An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made in a complaint or other document filed in a
lawsuit or other proceeding, if such filing is made under seal. An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the
trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal; and does not disclose the trade secret, except pursuant to court order.” I further understand that nothing contained
in this Agreement limits my ability to (A) communicate with any federal, state or local governmental agency or commission, including to provide documents or other information, without notice to Company, or (B) share compensation
information concerning myself or others, except that this does not permit me to disclose compensation information concerning others that I obtain because my job responsibilities require or allow access to such information. 

10. Nothing in or about this Agreement prohibits me from: (i) filing and, as provided for under Section 21F of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), maintaining the confidentiality of a claim with the Securities and Exchange Commission (the “SEC”), (ii) providing Proprietary Information or information about
this Agreement to the SEC, or providing the SEC with information that would otherwise violate any section of this Agreement, to the extent permitted by Section 21F of the Exchange Act, (iii) cooperating, participating or assisting in an
SEC investigation or proceeding without notifying the Company or (iv) receiving a monetary award as set forth in Section 21F of the Exchange Act. 

[Remainder of Page Intentionally Left Blank] 

  
 22 

 I HAVE READ THIS AGREEMENT CAREFULLY AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT
IMPOSES UPON ME WITHOUT RESERVATION. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY, IN DUPLICATE, WITH THE UNDERSTANDING THAT COMPANY WILL RETAIN ONE COUNTERPART
AND THE OTHER COUNTERPART WILL BE RETAINED BY ME. 
  

							
	_____________, 20___	 		 		 	Employee
				
		 		 		 	  

		 		 		 	Signature
				
		 		 		 	  

		 		 		 	Name (Printed)

  

			
	Accepted and Agreed to:
	CANO HEALTH, LLC

			
		
	By	 	  

		
	Name	 	  

		
	Title	 	

  
 23 

 APPENDIX A 

PRIOR MATTER 

  
 24 

 Exhibit C 

Form of Nonqualified Stock Option Award – Initial Award 

  
 25 

 Exhibit D 

Form of Restricted Stock Unit Award – Initial Award 

  
 26 

 Exhibit E 

Form of Nonqualified Stock Option Award – Annual Awards 

  
 27 

 Exhibit F 

Form of Restricted Stock Unit Award – Annual Awards 

  
 28 

 Exhibit G 

Form of Separation Agreement and Release of Claims 

  
 29Exhibit 4.1

 

NUMBER OF UNITS

U-           

SEE REVERSE FOR CERTAIN DEFINITIONS

 

CUSIP [ ]

 

OSIRIS ACQUISITION CORP.

UNITS CONSISTING OF ONE SHARE OF CLASS A COMMON STOCK AND

ONE-HALF OF ONE REDEEMABLE WARRANT, EACH WHOLE WARRANT ENTITLING 

THE HOLDER TO PURCHASE ONE SHARE OF

CLASS A COMMON STOCK

 

THIS CERTIFIES THAT                                   is the owner of
Units.

 

Each Unit (“Unit”) consists
of one (1) share of Class A common stock, par value $0.0001 per share (“Common Stock”), of Osiris Acquisition
Corp., a Delaware corporation (the “Company”), and one-half (1/2) of one warrant (each whole warrant a “Warrant”).
Each whole Warrant entitles the holder to purchase one (1) share (subject to adjustment) of Common Stock for $11.50 per share (subject
to adjustment). Only whole Warrants are exercisable. Each whole Warrant will become exercisable on the later of (i) thirty (30)
days after the Company’s completion of a merger, capital stock exchange, asset acquisition, stock purchase, reorganization
or other similar business combination with one or more businesses (each, a “Business Combination”), or (ii)
twelve (12) months from the closing of the Company’s initial public offering, and will expire unless exercised before 5:00
p.m., New York City Time, on the date that is five (5) years after the date on which the Company completes its initial Business
Combination, or earlier upon redemption or liquidation (the “Expiration Date”). The Common Stock and Warrants
comprising the Units represented by this certificate are not transferable separately prior to [ ], 2021, unless Jefferies LLC elects
to allow earlier separate trading, subject to the Company’s filing of a Current Report on Form 8-K with the Securities and
Exchange Commission containing an audited balance sheet reflecting the Company’s receipt of the gross proceeds of the Company’s
initial public offering and issuing a press release announcing when separate trading will begin. No fractional Warrants will be
issued upon separation of the Units and only whole Warrants will trade. The terms of the Warrants are governed by a Warrant Agreement,
dated as of [__], 2021, between the Company and Continental Stock Transfer & Trust Company, as Warrant Agent, and are subject
to the terms and provisions contained therein, all of which terms and provisions the holder of this certificate consents to by
acceptance hereof. Copies of the Warrant Agreement are on file at the office of the Warrant Agent at One State Street, 30th Floor,
New York, New York 10014, and are available to any Warrant holder on written request and without cost.

 

Upon the consummation of the Company’s
initial Business Combination, the Units represented by this certificate will automatically separate into the shares of Common Stocks
and Warrants comprising such Units.

 

This certificate is not valid unless countersigned
by the Transfer Agent and registered by the Registrar of the Company.

 

This certificate shall be governed by and
construed in accordance with the internal laws of the State of New York.

 

Witness the facsimile signature of its duly authorized officers.

 

	  	 	 
	Secretary	 	Chief Executive Officer

 

     

     

    

 

OSIRIS ACQUISITION CORP.

 

The Company will furnish without charge
to each unitholder who so requests, a statement of the powers, designations, preferences and relative, participating, optional
or other special rights of each class of stock or series thereof of the Company and the qualifications, limitations, or restrictions
of such preferences and/or rights.

 

The following abbreviations, when used in
the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable
laws or regulations:

 

	TEN COM	—	as tenants in common	UNIF GIFT MIN ACT —	Custodian
	 	 	 	 	 	 	 	 	 
	TEN ENT	—	as tenants by the entireties	 	(Cust) 	(Minor) 
	 	 	 	 	 
	JT TEN	—	as joint tenants with right of survivorship and not as tenants in common	 	
        under Uniform Gifts to Minors Act

        (State)

        

	 	 	 	 	 	 	 	 	 	 

Additional abbreviations may also be used
though not in the above list.

 

For value received, hereby sell, assign and transfer unto

 

PLEASE INSERT SOCIAL SECURITY OR

OTHER

IDENTIFYING NUMBER OF ASSIGNEE

 

(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS,
INCLUDING ZIP CODE, OF ASSIGNEE)

 

Units represented by the within Certificate, and do hereby
irrevocably constitute and appoint

 

Attorney to transfer the said Units on the books of the within
named Company with full power of substitution in the premises.

 

Dated

 

 

	 	Notice: The signature to this assignment must correspond
    with the name as written upon the face of the certificate in every particular, without alteration or enlargement or any change
    whatever.
	 	 
	Signature(s) Guaranteed:	 
	 
	 
	 
	THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND
CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15 (OR ANY SUCCESSOR
RULE).	 
	 

 

    2

     

    

 

In each case, as more fully described in the Company’s
final prospectus dated [ ], 2021, the holder(s) of the Company’s Class A common stock shall be entitled to receive a pro-rata
portion of certain funds held in the trust account established in connection with the Company’s initial public offering only
in the event that (i) the Company redeems the shares of Class A common stock sold in its initial public offering and liquidates
because it does not consummate an initial business combination by [ ], 2023 (or such later date if such period is extended pursuant
to the Company’s Certificate of Incorporation as in effect at such time), (ii) the Company redeems the shares of Class A
common stock in connection with an initial business combination (including the release of funds to pay any amounts due to any public
stockholders who properly exercise their redemption rights in connection therewith), (iii) the Company redeems the shares of Class
A common stock sold in its initial public offering in connection with a stockholder vote to approve an amendment to the Company’s
amended and restated certificate of incorporation that would affect the substance or timing of the Company’s obligation to
redeem 100% of the Class A common stock if it does not consummate an initial business combination by [ ], 2023 (or such later date,
if such period is extended pursuant to the Company’s Certificate of Incorporation as in effect at such time) or with respect
to any other material provisions relating to stockholders’ rights or pre-initial business combination activity, or (iv) if
the holder(s) seek(s) to redeem for cash his, her or its respective shares of Class A common stock in connection with a tender
offer (or proxy solicitation, solely in the event the Company seeks stockholder approval of the proposed initial business combination)
setting forth the details of a proposed initial business combination. In no other circumstances shall the holder(s) have any right
or interest of any kind in or to the trust account.

 

    3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]